Navigation Links
Inovio Pharmaceuticals to Present at Cowen & Co. Health Care Conference
Date:2/24/2011

esults may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, our ability to successfully integrate Inovio and VGX Pharmaceuticals, the impact of go
'/>"/>
SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Inovio Pharmaceuticals to Present at Partnering and Scientific Conferences
2. Inovio Pharmaceuticals Unveils Needle-free, Contactless Electroporation Technology for DNA Vaccine Delivery
3. Inovio Pharmaceuticals Dual-Antigen SynCon™ DNA Vaccine for Prostate Cancer Induces Robust Responses in Preclinical Trial
4. University of Southampton and Inovio Pharmaceuticals Initiate Phase 2 Clinical Study to Evaluate Leukemia DNA Vaccine Using Electroporation Delivery Technology
5. Inovio Pharmaceuticals Closes $24.3 Million Registered Offering
6. Jazz Pharmaceuticals to Present at the Citi 2011 Global Health Care Conference in New York on March 1
7. Tarix Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Study of TXA127 Following Autologous Peripheral Blood Stem Cell Transplant
8. Idenix Pharmaceuticals to Present at an Upcoming Investor Conference
9. Onyx Pharmaceuticals Reports Full Year and Fourth Quarter 2010 Financial Results
10. Avanir Pharmaceuticals to Present at Three Conferences in March
11. MAP Pharmaceuticals to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... -- Shire plc (LSE: SHP, NASDAQ: SHPG ... (CFO), has notified the Board of Directors of his decision to ... opportunity as CFO of Severn Trent plc.  James will leave Shire ... a search for a new CFO immediately. Flemming Ornskov, ... and lead a high-quality finance team at Shire. We are very ...
(Date:10/19/2014)... CTI BioPharma Corp. (CTI) (NASDAQ and MTA: ... quarter 2014 financial results on Wednesday, October 29, 2014, ... the announcement, members of the management team will host ... provide a general corporate update at 4:30 p.m. EDT ... obtained as follows: Wednesday, October 29 ...
(Date:10/19/2014)... N.Y. , Oct. 19, 2014  Henry Schein, ... provider of health care products and services to office-based ... it has invested in Iwase Dental Supply, Inc., a ... in Japan.  The transaction marks Henry Schein,s entrance into ... largest dental market, and increases to 28 the number ...
Breaking Medicine Technology:Interim Chief Financial Officer James Bowling to Step Down 2Interim Chief Financial Officer James Bowling to Step Down 3Interim Chief Financial Officer James Bowling to Step Down 4CTI BioPharma to Report Third Quarter 2014 Financial Results on October 29, 2014 2Henry Schein Enters Japan With Investment in Iwase Dental Supply 2Henry Schein Enters Japan With Investment in Iwase Dental Supply 3Henry Schein Enters Japan With Investment in Iwase Dental Supply 4Henry Schein Enters Japan With Investment in Iwase Dental Supply 5
... 18, 2011 The U.S. Food and Drug Administration ... treat patients with acute lymphoblastic leukemia (ALL), who have ... derived asparaginase and pegaspargase chemotherapy drugs used to treat ... Acute lymphoblastic leukemia is a type of ...
... and OXFORD, England, Nov. 18, 2011   EUSA Pharma, a ... supportive care and critical care, today announced that ... approved its orphan drug ERWINAZE™ (asparaginase Erwinia ... leukemia (ALL) in patients with hypersensitivity to ...
Cached Medicine Technology:FDA Approves Erwinaze to Treat a Form of Leukemia 2FDA Approves Erwinaze to Treat a Form of Leukemia 3EUSA Pharma Announces FDA Approval of Orphan Drug ERWINAZE™ for Treatment of Acute Lymphoblastic Leukemia 2EUSA Pharma Announces FDA Approval of Orphan Drug ERWINAZE™ for Treatment of Acute Lymphoblastic Leukemia 3EUSA Pharma Announces FDA Approval of Orphan Drug ERWINAZE™ for Treatment of Acute Lymphoblastic Leukemia 4
(Date:10/20/2014)... My Clients Plus ( http://www.MyClientsPlus.com ) ... The new module enables easy administration and routing of ... care. , This application allows users such as Therapists ... a to-do item to a specific client, categorize tasks ... reoccurring reminders for follow-ups. It's designed to enable ...
(Date:10/20/2014)... 2014 Principle Business Enterprises, a family ... manufacturing top-of-the-line absorbent products. The company has recently ... popular brand, Tranquility® Premium Protection absorbent products. The ... gave its packaging a new look, and is currently ... to the public. , The new website, developed with ...
(Date:10/20/2014)... CA (PRWEB) October 20, 2014 AttorneyOne.com, a ... the latest information from the FDA on Sit and ... October 10 not to purchase or use Sit and Slim ... and Slim II is promoted as weight loss product on ... removed from the market in 2010 for safety reasons, can ...
(Date:10/20/2014)... 2014 Myoderm announced ... Director of their CentralSource service. Matthew ... innovative turnkey drug sourcing, distribution, and management service ... 12 years of industry experience, in both business ... peak of their international success to help clients ...
(Date:10/20/2014)... OH (PRWEB) October 20, 2014 ... Assisted Living Center on Oct. 14. The $11 million ... and services, and a cooked-to-order kitchen with full-service restaurant ... Akron’s premier choice for first class Assisted Living apartments,” ... “Our residents deserve the highest quality of care and ...
Breaking Medicine News(10 mins):Health News:My Clients Plus Announces New Workflow Management Software 2Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2Health News:Rockynol Retirement Community Expands Assisted Living Center 2
... in US are not getting ample amounts of a nutrient ... development.// ,A new study sponsored by the National ... the top universities in America has suggested that the women ... is required to promote normal fetal brain development. ...
... deleterious effect on young, developing brains, according to researchers ... linked to lower IQ scores later in life. // ... diabetes, high cholesterol and hypertension is a well documented ... genetics at the University of Florida said, 'We're postulating ...
... after they received blood transfusion thought to be contaminated ... been// infected in the last few months in various ... died were all younger than two years old," a ... suspected donors who are thought to have HIV.HIV/AIDS infection ...
... the University of Virginia Health System have found that ... drive better when they took// OROS methylphenidate (OROS MPH), ... (se-AMPH ER). The findings, which reinforce the use of ... ADHD, will appear in the Sept. issue of Pediatrics. ...
... has been released by Australian obesity experts that show gastric ... conference on obesity in Sydney there were three studies which ... in mortality rates in obese people who had the surgery. ... upper part of the stomach for the procedure to restrict ...
... in children that can often be disabling and one ... from school could mainly be due to their genetic// ... Medicine (Department of Psychological Medicine), in a genetic study ... usually occur together, they are of different genetic and ...
Cached Medicine News:Health News:Americans Deficient In Dietary Intake Of Choline Needed for Fetal Brain Development 2Health News:Americans Deficient In Dietary Intake Of Choline Needed for Fetal Brain Development 3Health News:Obesity Takes its Toll on IQ of Toddlers 2Health News:Not All ADHD Drugs Are Equal 2
Listeria Enrichment Broth...
... Thermomixer R offers maximum application versatility ... heating, and cooling. Its active heating/cooling ... and temperature control ranges. Five different ... micro test tubes, are available for: ...
... units Penicillin/25,000 ug Streptomycin ... Reagent and Buffer products ... with cGMP regulations and ... to assure compatibility. , ...
...
Medicine Products: